Outcomes for Women With Ductal Carcinoma-in-Situ and a Positive Sentinel Node: A Multi-Institutional Audit

Moore, K.; Sweeney, Karl; Wilson, M; Goldberg, Jessica; Buchanan, Claire; Tan, Lee K.; Liberman, Laura; Turner, Roderick R.; Lagios, Michael D.; Cody, Hiram S.; Giuliano, Armando E.; Silverstein, Melvin J.; Zee, Kimberly J. Van

doi:10.1245/s10434-007-9414-8

Cited by 65 publications

(39 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reference Klauber-DeMore et al 29 Pendas et al 19 Mittendorf et al 31 Camp et al 32 Yen et al 33 Takacs et al 34 Fraile et al 35 Moran et al 36 Meijnen et al 37 Moore et al 38 Cox et al 18 For example, some reports doubled their node positivity frequencies by using immunohistochemistry to detect SLN involvement 14,18,30 . The differences in the reported frequencies of nodal metastases may also reflect the patient populations studied.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of sentinel node biopsy in ductal carcinomain situof the breast

Ansari

Ogston

Purdie

et al. 2008

British Journal of Surgery

105

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Meta-analysis of sentinel node biopsy in ductal carcinomain situof the breast

Ansari

Ogston

Purdie

et al. 2008

British Journal of Surgery

105

View full text Add to dashboard Cite

show abstract

“…In the few cases published in the literature [63,[68][69][70][78][79][80][81], in which AD was performed after an positive SLNB, in all cases but one (67/68, 98,5%) all the non-SLNs were negative and the SLN already biopsied was the only positive LN. That is why we conclude that in cases of DIN patients with a positive SLNB, AD should not be immediately performed except for only those cases that present mammary invasion on final pathologic evaluation.…”

Section: Surgical Treatmentmentioning

confidence: 95%

The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy

Farante

Zurrida

Galimberti

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…At a median follow-up of 102 months, all patients remained free of disease. Moore et al 28 found 43 (9.1%) positive sentinel nodes in 470 patients with high-risk DCIS: 36 with ITCs, 4 with micrometastases, and 3 with macrometastases. Of 25 patients who underwent ALND, only 1 was found to have additional positive nodes.…”

Section: Sentinel Node Biopsy: Reducing the Morbidity Of Axillary Stamentioning

confidence: 99%

Clinical applications of breast pathology: management of in situ breast carcinomas and sentinel node biopsy issues

Smith

2010

Modern Pathology

View full text Add to dashboard Cite

The purpose of this article is to review the current clinical management of in situ breast carcinomas, including how specific aspects of a pathology report are used in clinical decision-making, and to discuss the current role of sentinel node biopsy in management of invasive breast carcinomas and ductal carcinoma in situ of the breast. Sentinel node biopsy: reducing the morbidity of axillary stagingThe pathological status of axillary lymph nodes remains one of the most important prognostic factors in patients with breast cancer. Identification of metastatic tumor deposits in the axillary nodes indicates a poorer prognosis and often prompts a recommendation for more aggressive systemic and local therapies. Surgical staging of the axilla is a routine component of breast cancer treatment for the majority of the 200 000 patients diagnosed with invasive breast cancer in the United States each year.Unfortunately, axillary dissection is often the main source of morbidity in patients with earlystage breast cancer. Immediate problems include acute pain, the need for hospital stay, reduced range of motion, and the need for a drain in the surgical bed for a week or more. Long-term problems resulting from axillary dissection include permanent lymphedema in up to 35% of patients, numbness in 35%, chronic pain in 10%, and reduced range of motion in 5-10%.2-13 An assessment of patients' subjective symptoms of arm problems shows even higher rates of persistent arm symptoms, with 25-50% of patients reporting arm swelling, pain, numbness, and/or decreased mobility.10,14-16 Studies of quality of life in patients treated for breast cancer have shown prolonged decreases in quality of life for those with lymphedema and other chronic arm symptoms resulting from axillary dissection. [7][8][9]17 At present, there are no effective therapies to reverse established lymphedema.2 As lymphedema after axillary dissection cannot be 'cured', or even reliably prevented, identification of alternatives to standard axillary dissection have been sought.The technique of sentinel node biopsy was developed with the aim of reducing the morbidity of surgical staging of the axilla. Identification of the first or 'sentinel' nodes draining the affected breast using radioactive particles 18 or blue dye 19 has allowed selective and minimally traumatic excision of only the most informative axillary nodes. Morbidity rates are substantially lower with sentinel node biopsy compared with axillary dissection.6,17-23 Acutely, sentinel node biopsy is an

show abstract

Outcomes for Women With Ductal Carcinoma-in-Situ and a Positive Sentinel Node: A Multi-Institutional Audit

Abstract: SLN biopsy for high-risk DCIS patients is a mean of detecting those who may have unrecognized invasive disease and therefore are at risk for distant disease.

Cited by 65 publications

References 23 publications

Meta-analysis of sentinel node biopsy in ductal carcinomain situof the breast

Meta-analysis of sentinel node biopsy in ductal carcinomain situof the breast

The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy

Clinical applications of breast pathology: management of in situ breast carcinomas and sentinel node biopsy issues

Contact Info

Product

Resources

About